Mesothelioma Clinical Trials (June 2026): 70 Recruiting Interventional Studies

Last updated: June 15, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Unresectable / Advanced Mesothelioma

First-line and beyond for patients not eligible for surgery:

• Checkpoint + TKI or anti-VEGF combinations:
  • NCT05188859 - Sintilimab + Anlotinib + platinum doublet (1L pleural, Phase 2)
  • NCT06543069 - Sintilimab + Bevacizumab + Pemetrexed/Cisplatin (unresectable, Phase 2)
• PD-1/CTLA-4 bispecific:
  • NCT06535607 - Volrustomig (PD-1/CTLA-4 bispecific) in unresectable pleural mesothelioma — sub-study 5 of the eVOLVE-02 platform (Phase 2)
• Vaccine + checkpoint inhibitor:
  • NCT05765084 - Atezolizumab + WT1/dendritic cell vaccine + platinum/pemetrexed (1L epithelioid pleural mesothelioma, Phase 1/2)
• Novel immunotherapy:
  • NCT04400539 - 5-ALA photodynamic therapy + immunotherapy (Phase 2)

Resectable / Surgery Combinations

Neoadjuvant and adjuvant immunotherapy with surgery:

• NCT04996017 - Atezomeso (Phase 3): adjuvant atezolizumab vs placebo after surgery for malignant pleural mesothelioma — the only currently recruiting Phase 3 mesothelioma trial
• NCT05932199 - Neoadjuvant Durvalumab + Tremelimumab ± chemotherapy (Phase 1/2)
• NCT03760575 - Pembrolizumab + chemotherapy + image-guided surgery (Phase 1)
• NCT05647265 - Immunotherapy before surgery (sarcomatoid subtype, Phase 2)
• NCT07121374 - NECIM: neoadjuvant chemo-immunotherapy for selected inoperable pleural mesothelioma (Phase 1/2)

Peritoneal Mesothelioma

Trials specifically for peritoneal disease:

• NCT06057935 - Additional chemotherapy after surgery (Phase 2)
• NCT05001880 - Chemotherapy ± immunotherapy for peritoneal mesothelioma (Phase 2)
• NCT07510815 - Dual-target MSLN/FAP CAR-NK cells — explicitly enrolls peritoneal mesothelioma (Phase 1/2)
• NCT06756035 - CT-95 mesothelin agent — eligibility includes malignant peritoneal mesothelioma (Phase 1a/1b)

Biomarker-Selected Trials

Two biomarker-defined trials worth flagging early in your search — both require molecular testing your pathology report (BAP1 IHC, HRD panel, MTAP IHC/FISH, CDKN2A loss) may already cover. If not, ask your oncologist whether archival tumor can be re-tested.

BAP1 / HRD-selected (Olaparib, Phase 2)

• NCT04515836 - Olaparib in patients with HRD malignant mesothelioma (Phase 2). BAP1 loss and other DNA-repair (homologous recombination) defects are common in mesothelioma; this trial tests the PARP inhibitor olaparib in that selected population.

MTAP-deficient relapsed mesothelioma (SELECTmeso platform)

• NCT07602946 - SELECTmeso1 (Phase 2): BMS-986504 in patients with MTAP-deficient relapsed mesothelioma. MTAP loss often co-occurs with CDKN2A homozygous deletion (a hallmark of mesothelioma) and creates a synthetic-lethal vulnerability targeted by PRMT5 inhibitors. SELECTmeso is the new UK precision-medicine platform trial for relapsed mesothelioma. Status: NOT_YET_RECRUITING — opening soon; ask your sponsor center.

Trials by Treatment Approach

Checkpoint Inhibitors

PD-1/PD-L1 and CTLA-4 inhibitors, often combined with chemotherapy or targeted agents — including the adjuvant Phase 3 Atezomeso trial (NCT04996017). View all →

Mesothelin-Targeted Therapies

CAR-T cells, CAR-NK, and small-molecule / antibody agents targeting mesothelin, which is highly expressed on mesothelioma. View all →

• NCT06885697 - Anti-mesothelin TNaive/SCM hYP218 (TNhYP218) CAR-T cells in mesothelin-expressing solid tumors including mesothelioma (Phase 1)
• NCT06051695 - Logic-gated mesothelin CAR-T for solid tumors that express MSLN and have lost HLA-A*02 (Phase 1/2)
• NCT05568680 - SynKIR-110 for mesothelin-expressing tumors (ovarian, cholangiocarcinoma, mesothelioma; Phase 1)
• NCT06756035 - CT-95 mesothelin-directed agent in pleural and peritoneal mesothelioma and other mesothelin-expressing tumors (Phase 1a/1b, first-in-human)
• NCT07510815 - Dual-target MSLN/FAP CAR-NK cells for pleural and peritoneal mesothelioma (Phase 1/2)

Surgery Combinations

Pleurectomy/decortication or extrapleural pneumonectomy combined with neoadjuvant, adjuvant, or perioperative systemic therapy. View all →

Antibody-Drug Conjugates

Two ADC trials specifically open to mesothelioma patients. Both require specific eligibility — ask about IHC testing on archival biopsy:

• NCT06477419 - Sacituzumab govitecan (Trodelvy, TROP2 ADC) in mesothelioma (Phase 2). Already FDA-approved for triple-negative and HR+ breast cancer; this study tests it in mesothelioma.
• NCT03007030 - Brentuximab vedotin in CD30+ malignant mesothelioma (Phase 2). Requires CD30 positivity by IHC — not all mesothelioma expresses CD30, so testing first.

Frequently Asked Questions